Adjuvant Everolimus Falls Short in High-Risk Renal Cancer
Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized phase III trial. The so-called EVEREST study showed that among 1,545 patients with histologically confirmed RCC who had undergone a full surgical resection, […]